Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Universal Cells Inc.

http://www.universalcells.com/

Latest From Universal Cells Inc.

Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko

Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.

Business Strategies Research and Development Strategies

Asia Deal Watch: BeiGene Gets Chinese Rights To Two EUSA Rare Disease Therapies

BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.

Deals Business Strategies

Adaptimmune And Astellas Team Up For Off-The-Shelf T-Cell Therapies

News of the deal emerged as the UK firm's shares skyrocketed after its SPEAR T-cell platform delivered responses in four solid tumor types.

ImmunoOncology Deals

Early-Stage Cell And Gene Therapy Progress: Updates From Casebia, BlueRock, Athersys, Cynata

Scrip caught up with several companies during the recent Cell and Gene Meeting on the Mesa, sponsored by the Alliance for Regenerative Medicine.

Regenerative Medicine Business Strategies
See All

Company Information

UsernamePublicRestriction

Register